Top

Published in:

01-08-2014 | Research Paper

High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma

Authors: Marcos Vinícius Macedo de Oliveira, Carlos Alberto de Carvalho Fraga, Lucas Oliveira Barros, Camila Santos Pereira, Sérgio Henrique Sousa Santos, John R. Basile, Ricardo Santiago Gomez, André Luiz Sena Guimarães, Alfredo Maurício Batista De-Paula

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Abstract

The presence of cervical metastasis is responsible for high morbidity and mortality rates in individuals with head and neck squamous cell carcinoma (HNSCC). S100A4, a pleiotropic EF-hand calcium-binding protein, is expressed in various normal and cancer cell types. During cancer progression, molecular disturbances in S100A4 can modulate the activity and expression of pre-metastatic and metastatic genes. In this study, we investigated the association between S100A4 methylation status and protein expression as well as the expression of the S100A4 related-proteins annexin A2 (ANXA2), matrix metallopeptidase-9, and endoglin, for metastasis and other clinicopathological parameters in HNSCC. Formalin-fixed, paraffin-embedded blocks of metastatic and non-metastatic HNSCC and matched cervical lymph node (LN) samples (metastatic LN = mLN, non-metastatic = nmLN, and control LN (lymphadenitis) = cLN) were submitted for methylation specific-polymerase chain reaction and immunohistochemistry. Our results showed that S100A4 methylation status failed to demonstrate association with cervical metastasis and other clinicopathological factors related to HNSCC. HNSCC samples from patients that presented with metastatic disease showed high S100A4 and endoglin expression (p < 0.05). In conclusion, molecular disturbances in S100A4 and endoglin expression might regulate the formation of cervical metastasis in HNSCC.

Available only for authorised users

Jemal A, Siegel R, Xu J (2010) Ward E (2010) cancer statistics. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073 PubMed

Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45(4–5):309–316. doi:10.1016/j.oraloncology.2008.06.002 PubMedCrossRef

Curado MP, Boyle P (2013) Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol 25(3):229–234. doi:10.1097/CCO.0b013e32835ff48c PubMed

De Paula AM, Souza LR, Farias LC, Correa GT, Fraga CA, Eleuterio NB, Silveira AC, Santos FB, Haikal DS, Guimaraes AL, Gomez RS (2009) Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol 45(9):777–782PubMedCrossRef

Rothenberg SM, Ellisen LW (2012) The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 122(6):1951–1957PubMedCentralPubMedCrossRef

Hiratsuka H, Miyakawa A, Nakamori K, Kido Y, Sunakawa H, Kohama G (1997) Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer 80(3):351–356. doi:10.1002/(SICI)1097-0142(19970801)80 PubMedCrossRef

Descot A, Oskarsson T (2013) The molecular composition of the metastatic niche. Exp Cell Res. doi:10.1016/j.yexcr.2013.04.017 PubMed

Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128(11):2527–2535. doi:10.1002/ijc.26031 PubMedCentralPubMed

Peinado H, Lavotshkin S, Lyden D (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21(2):139–146. doi:10.1016/j.semcancer.2011.01.002 PubMedCrossRef

10.

Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, Ruegg C (2012) Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol 22(3):174–186. doi:10.1016/j.semcancer.2012.02.007 PubMedCrossRef

11.

Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33(7):637–668PubMed

12.

Polans AS, Palczewski K, Asson-Batres MA, Ohguro H, Witkowska D, Haley TL, Baizer L, Crabb JW (1994) Purification and primary structure of Capl, an S-100-related calcium-binding protein isolated from bovine retina. J Biol Chem 269(8):6233–6240PubMed

13.

Boye K, Maelandsmo GM (2010) S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176(2):528–535. doi:10.2353/ajpath.2010.090526 PubMedCentralPubMedCrossRef

14.

Garrett SC, Varney KM, Weber DJ, Bresnick AR (2006) S100A4, a mediator of metastasis. J Biol Chem 281(2):677–680PubMedCrossRef

15.

Lukanidin E, Sleeman JP (2012) Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol 22(3):216–225. doi:10.1016/j.semcancer.2012.02.006 PubMedCrossRef

16.

Grieve AG, Moss SE, Hayes MJ (2012) Annexin A2 at the interface of actin and membrane dynamics: a focus on its roles in endocytosis and cell polarization. Int J Cell Biol 2012:852430. doi:10.1155/2012/852430 PubMedCentralPubMed

17.

Sharma M, Ownbey RT, Sharma MC (2010) Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88(2):278–286. doi:10.1016/j.yexmp.2010.01.001 PubMedCrossRef

18.

Lokman NA, Ween MP, Oehler MK, Ricciardelli C (2011) The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron 4(2):199–208. doi:10.1007/s12307-011-0064-9 PubMedCentralPubMedCrossRef

19.

Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37(6):375–536. doi:10.1080/10409230290771546 PubMedCrossRef

20.

Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 98(22):12485–12490. doi:10.1073/pnas.171460498 PubMedCentralPubMedCrossRef

21.

Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744. doi:10.1038/35036374 PubMedCentralPubMed

22.

Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274(19):13066–13076PubMedCrossRef

23.

Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176PubMedCentralPubMed

24.

Fonsatti E, Maio M (2004) Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Trans Med 2(1):18CrossRef

25.

Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP (1999) Defective angiogenesis in mice lacking endoglin. Science 284(5419):1534–1537PubMedCrossRef

26.

Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23(20):4018–4028. doi:10.1038/sj.emboj.7600386 PubMedCentralPubMedCrossRef

27.

She X, Matsuno F, Harada N, Tsai H, Seon BK (2004) Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 108(2):251–257. doi:10.1002/ijc.11551 PubMed

28.

Kuiper P, Hawinkels LJ, de Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW (2011) Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 17(2):219–225. doi:10.3748/wjg.v17.i2.219 PubMedCentralPubMedCrossRef

29.

Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17(2):197–203PubMedCrossRef

30.

Lo JF, Yu CC, Chiou SH, Huang CY, Jan CI, Lin SC, Liu CJ, Hu WY, Yu YH (2011) The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res 71(5):1912–1923. doi:10.1158/0008-5472.CAN-10-2350 PubMedCrossRef

31.

Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Sasaki T, Yamamoto E (2004) Correlation of S100A4 expression with invasion and metastasis in oral squamous cell carcinoma. Oral Oncol 40(5):496–500PubMedCrossRef

32.

Sapkota D, Bruland O, Boe OE, Bakeer H, Elgindi OA, Vasstrand EN, Ibrahim SO (2008) Expression profile of the S100 gene family members in oral squamous cell carcinomas. JOral PatholMed 37(10):607–615. doi:10.1111/j.1600-0714.2008.00683.x

33.

Broders AC (1921) Squamous-cell epithelioma of the skin: a study of 256 cases. Ann Surg 73(2):141–160PubMedCentralPubMedCrossRef

34.

Bryne M, Koppang HS, Lilleng R, Kjaerheim A (1992) Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166(4):375–381PubMedCrossRef

35.

Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M (2006) DNA methylation: bisulphite modification and analysis. Nat Protoc 1(5):2353–2364. doi:10.1038/nprot.2006.324 PubMedCrossRef

36.

Reinders J, 12 (2009) Amplification of bisulfite-converted DNA for genome-wide DNA methylation profiling. Cold Spring Harb Protoc 2009:pdb.prot5342. doi:10.1101/pdb.prot5342 PubMedCrossRef

37.

Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A(14):2474–2484PubMedCrossRef

38.

Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147(1):9–19PubMedCentralPubMed

39.

Bird A (1992) The essentials of DNA methylation. Cell 70(1):5–8PubMedCrossRef

40.

Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10(7):687–692PubMedCrossRef

41.

Ehrlich M (2009) DNA hypomethylation in cancer cells. Epigenomics 1(2):239–259. doi:10.2217/epi.09.33 PubMedCentralPubMedCrossRef

42.

Li Y, Liu ZL, Zhang KL, Chen XY, Kong QY, Wu ML, Sun Y, Liu J, Li H (2009) Methylation-associated silencing of S100A4 expression in human epidermal cancers. Exp Dermatol 18(10):842–848PubMedCrossRef

43.

Liu J, Guo Y, Fu S, Yang M, Sun KL, Fu WN (2010) Hypomethylation-induced expression of S100A4 increases the invasiveness of laryngeal squamous cell carcinoma. Oncol Rep 23(4):1101–1107PubMedCrossRef

44.

Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR (2007) Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol 20(10):1045–1054PubMedCrossRef

45.

Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA (2010) Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights 5:9–20PubMedCentralPubMedCrossRef

46.

Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Miyamori H, Sato H, Yamamoto E, Sasaki T (2005) S100A4 regulates E-cadherin expression in oral squamous cell carcinoma. Cancer Lett 230(2):211–218PubMedCrossRef

47.

Chen M, Sinha M, Luxon BA, Bresnick AR, O’Connor KL (2009) Integrin α6β4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 284(3):1484–1494. doi:10.1074/jbc.M803997200 PubMedCentralPubMedCrossRef

48.

Li ZH, Bresnick AR (2006) The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res 66(10):5173–5180PubMedCrossRef

49.

Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, Maelandsmo GM (1999) S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59(18):4702–4708PubMed

50.

Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N (2004) Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 23(32):5487–5495PubMedCrossRef

51.

Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V (2005) Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation. JBiolChem 280(21):20833–20841

52.

Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 97(6):2626–2631PubMedCentralPubMedCrossRef

53.

Fraga CA, De Oliveira MV, de Oliveira ES, Barros LO, Santos FB, Gomez RS, De-Paula AM, Guimaraes AL (2011) A high HIF-1alpha expression genotype is associated with poor prognosis of upper aerodigestive tract carcinoma patients. Oral Oncol. doi:10.1016/j.oraloncology.2011.08.023 PubMed

54.

Kyzas PA, Agnantis NJ, Stefanou D (2006) Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 448(6):768–775. doi:10.1007/s00428-006-0195-4 PubMedCrossRef

55.

Marioni G, D’Alessandro E, Giacomelli L, Staffieri A (2010) CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J Oral Pathol Med 39(5):361–367. doi:10.1111/j.1600-0714.2010.00888.x PubMed

56.

Rafii S, Lyden D (2006) S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 8(12):1321–1323. doi:10.1038/ncb1206-1321 PubMedCentralPubMed

57.

Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395–406. doi:10.1083/jcb.201102147 PubMedCentralPubMedCrossRef

58.

Rucci N, Sanita P, Angelucci A (2011) Roles of metalloproteases in metastatic niche. Curr Mol Med 11(8):609–622PubMedCrossRef

Title: High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma
Authors: Marcos Vinícius Macedo de Oliveira
Carlos Alberto de Carvalho Fraga
Lucas Oliveira Barros
Camila Santos Pereira
Sérgio Henrique Sousa Santos
John R. Basile
Ricardo Santiago Gomez
André Luiz Sena Guimarães
Alfredo Maurício Batista De-Paula
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-014-9655-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

Living in shear: platelets protect cancer cells from shear induced damage

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs

Metadherin expression and lung relapse in patients with colorectal carcinoma

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer